Eton Pharmaceuticals (NASDAQ:ETON) has submitted a new drug application (NDA) for dehydrated alcohol injection, previously known as DS-100, to the FDA for the treatment of methanol poisoning.
The filing is the company’s second for an orphan drug candidate and fifth total candidate under FDA review.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.